GlaxoSmithKline plc Rating Reiterated by Societe Generale (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating restated by equities researchers at Societe Generale in a research report issued on Wednesday. They currently have a GBX 2,050 ($34.51) target price on the stock. Societe Generale’s price objective would suggest a potential upside of 25.41% from the company’s current price.
Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.65% on Wednesday, hitting GBX 1607.5001. 4,065,956 shares of the company’s stock traded hands. GlaxoSmithKline plc has a 1-year low of GBX 1200.668 and a 1-year high of GBX 1816.00. The stock has a 50-day moving average of GBX 1611. and a 200-day moving average of GBX 1618.. The company’s market cap is £77.385 billion.
The company also recently announced a dividend, which is scheduled for Thursday, July 10th. Shareholders of record on Wednesday, May 14th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.17%. The ex-dividend date is Wednesday, May 14th.
A number of other analysts have also recently weighed in on GSK. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, May 23rd. They now have a GBX 1,660 ($27.94) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of GlaxoSmithKline plc in a research note on Thursday, May 22nd. They now have a GBX 1,650 ($27.77) price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, May 21st. They now have a GBX 1,730 ($29.12) price target on the stock. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. GlaxoSmithKline plc presently has an average rating of “Hold” and an average price target of GBX 1,710.61 ($28.79).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.